GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Akebia Therapeutics Inc (STU:AX9) » Definitions » Net Margin %

Akebia Therapeutics (STU:AX9) Net Margin % : -53.54% (As of Sep. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Akebia Therapeutics Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. Akebia Therapeutics's Net Income for the three months ended in Sep. 2024 was €-18.1 Mil. Akebia Therapeutics's Revenue for the three months ended in Sep. 2024 was €33.7 Mil. Therefore, Akebia Therapeutics's net margin for the quarter that ended in Sep. 2024 was -53.54%.

The historical rank and industry rank for Akebia Therapeutics's Net Margin % or its related term are showing as below:

STU:AX9' s Net Margin % Range Over the Past 10 Years
Min: -8843.45   Med: -76.3   Max: -26.68
Current: -27.07


STU:AX9's Net Margin % is ranked worse than
79.5% of 995 companies
in the Drug Manufacturers industry
Industry Median: 3.96 vs STU:AX9: -27.07

Akebia Therapeutics Net Margin % Historical Data

The historical data trend for Akebia Therapeutics's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Akebia Therapeutics Net Margin % Chart

Akebia Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -83.48 -130.61 -133.25 -32.22 -26.68

Akebia Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -34.46 1.09 -55.16 -19.66 -53.54

Competitive Comparison of Akebia Therapeutics's Net Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, Akebia Therapeutics's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Akebia Therapeutics's Net Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Akebia Therapeutics's Net Margin % distribution charts can be found below:

* The bar in red indicates where Akebia Therapeutics's Net Margin % falls into.



Akebia Therapeutics Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Akebia Therapeutics's Net Margin for the fiscal year that ended in Dec. 2023 is calculated as

Net Margin=Net Income (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-47.615/178.469
=-26.68 %

Akebia Therapeutics's Net Margin for the quarter that ended in Sep. 2024 is calculated as

Net Margin=Net Income (Q: Sep. 2024 )/Revenue (Q: Sep. 2024 )
=-18.055/33.723
=-53.54 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Akebia Therapeutics  (STU:AX9) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.


Akebia Therapeutics Net Margin % Related Terms

Thank you for viewing the detailed overview of Akebia Therapeutics's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Akebia Therapeutics Business Description

Traded in Other Exchanges
Address
245 First Street, Suite 1400, Cambridge, MA, USA, 02142
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor, is approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.

Akebia Therapeutics Headlines

No Headlines